荣泰健康(603579) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥385,718,637.33, representing a decrease of 31.71% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥37,501,251.13, down 35.70% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,866,712.47, a decline of 39.52% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.28, reflecting a decrease of 36.36% year-over-year[6] - The diluted earnings per share for Q1 2023 was also ¥0.28, down 33.33% from the same period last year[6] - Total operating revenue for Q1 2023 was CNY 385.72 million, a decrease of 31.7% compared to CNY 564.80 million in Q1 2022[19] - Net profit for Q1 2023 was CNY 37.68 million, a decline of 35.6% from CNY 58.56 million in Q1 2022[20] - Basic earnings per share for Q1 2023 were CNY 0.28, compared to CNY 0.44 in Q1 2022[21] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,259,730,630.27, down 4.79% from the end of the previous year[6] - Total assets as of Q1 2023 were CNY 3.26 billion, a decrease from CNY 3.42 billion at the end of Q1 2022[16] - Total liabilities as of Q1 2023 were CNY 1.35 billion, down from CNY 1.55 billion in Q1 2022[16] - Shareholders' equity attributable to the parent company was ¥1,903,618,815.29, an increase of 2.01% compared to the end of the previous year[6] - Shareholders' equity as of Q1 2023 was CNY 1.91 billion, an increase from CNY 1.87 billion in Q1 2022[17] Cash Flow - The company reported a net cash flow from operating activities of ¥21,078,065.76 for Q1 2023, with no applicable year-over-year comparison[5] - The net cash flow from operating activities for Q1 2023 was 21,078,065.76, a significant improvement from -27,415,890.24 in Q1 2022, indicating a recovery in operational efficiency[24] - Total cash inflow from operating activities was 448,101,157.18, while cash outflow was 427,023,091.42, resulting in a net cash inflow of 21,078,065.76 for the quarter[24] - Cash received from sales of goods and services in Q1 2023 was CNY 392.97 million, down 33.2% from CNY 589.07 million in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were 1,242,747,863.10, down from 1,284,376,555.91 at the end of Q1 2022[25] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 17.23 million, a decrease of 31.5% from CNY 25.17 million in Q1 2022[19] - Financial expenses for Q1 2023 were CNY 5.39 million, compared to CNY 4.86 million in Q1 2022[20] - Cash inflow from investment activities was 237,989,336.56, compared to 612,494,044.13 in the previous year, reflecting a decrease in investment returns[25] - The cash outflow for investment activities was 194,998,606.79, down from 542,435,408.90 in Q1 2022, suggesting a reduction in capital expenditures[25] Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement, which is still pending court judgment[13] - The company has taken proactive measures to respond to the ongoing litigation and is contesting the claims made against it[13] - The company has not provided specific guidance for future performance in this report, but it is actively monitoring market conditions and legal developments[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,229[10] - The company reported a total of 3,348,479 shares held in its repurchase account, accounting for 2.39% of the total shares as of March 31, 2023[12] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 1.99%, a decrease of 1.24 percentage points compared to the end of the previous year[6] - As of March 31, 2023, the company's cash and cash equivalents amounted to RMB 1,242,747,863.10, a decrease from RMB 1,329,776,484.49 as of December 31, 2022, representing a decline of approximately 6.5%[14] - The total current assets as of March 31, 2023, were RMB 2,038,128,218.89, down from RMB 2,270,578,335.21 at the end of 2022, indicating a decrease of about 10.2%[15] - The company's accounts receivable increased to RMB 106,227,100.14 from RMB 95,069,521.56, reflecting a growth of approximately 11.4%[15] - The inventory level decreased to RMB 177,040,326.87 from RMB 205,227,948.56, showing a reduction of around 13.7%[15] - Long-term equity investments were reported at RMB 58,586,718.35, slightly down from RMB 59,082,899.43, indicating a decrease of about 0.8%[15] - The total non-current assets as of March 31, 2023, were RMB 1,221,602,411.38, an increase from RMB 1,153,246,826.81 at the end of 2022, representing a growth of approximately 5.9%[15]